News | July 31, 2024
Boehringer Ingelheim acquires Nerio Therapeutics for US$ 1.3bn
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
Decision on EU marketing authorisation for this population expected by September 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Doxorubicin Hydrochloride Liposome Injection (RLD Doxil) had estimated annual sales of USD 42 million in the U.S. (IQVIA MAT May 2024)
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Subscribe To Our Newsletter & Stay Updated
